 |
|
Provision of Pneumococcal Prophylaxis for Publicly Insured Children With Sickle Cell Disease
Colin M. Sox, MD;
William O. Cooper, MD, MPH;
Thomas D. Koepsell, MD, MPH;
David L. DiGiuseppe, MSc;
Dimitri A. Christakis, MD, MPH
JAMA. 2003;290:1057-1061.
Context It is recommended that children younger than 5 years with sickle cell disease (SCD) take daily prophylactic antibiotics to prevent pneumococcal infections; however, how much prophylactic medication they actually are dispensed is unclear.
Objectives To measure the amount of prophylactic antibiotics dispensed to young children with SCD and to investigate factors associated with increased delivery of medication.
Design, Setting, and Patients Retrospective longitudinal study conducted January 1995 through December 1999 using Tennessee and Washington State Medicaid administrative claims and encounter data. Children (N = 261) who had 1 inpatient or 2 outpatient claims or encounters listing an International Classification of Diseases, Ninth Revision, Clinical Modification code for SCD, were younger than 4 years at study entry (mean age, 1.4 years), and were continuously enrolled in Medicaid for a 1-year period.
Main Outcome Measure Number of days during a 365-day period covered by prescription fills for a penicillin or macrolide antibiotic, or for trimethoprim-sulfamethoxazole.
Results In a 365-day period, patients were dispensed a mean of 148.4 (SD, 121.3; median, 114; interquartile range [IQR], 39-247) days of prophylactic medication. The total amount of medication dispensed varied widely: 10.3% of patients received none and 21.5% received more than 270 days of medication. In a 365-day period, a mean of 12.7 (SD, 10.5; range, 0-40) prophylactic prescriptions were filled per patient. The median prescription duration was 10 days. In a multivariate linear regression model adjusting for state, sex, age at study entry, inclusion year, residence in urban community, outpatient inclusion encounter, required prescription co-payment, and number of outpatient visits for nonpreventive care, each preventive visit was associated with 12.0 (95% confidence interval [CI], 2.3-21.7) additional days of prophylactic antibiotics, and each emergency department visit was associated with 10.0 (95% CI, 1.2-18.8) additional days.
Conclusions Publicly insured children with SCD may receive inadequate antibiotic prophylaxis against pneumococcal infections, placing them at increased risk of morbidity and mortality; however, increased numbers of outpatient visits for preventive care are associated with improved provision of prophylactic antibiotics.
Author Affiliations: Departments of Pediatrics (Drs Sox and Christakis) and Epidemiology (Dr Koepsell), University of Washington, Seattle; Child Health Institute (Mr DiGiuseppe and Dr Christakis), Seattle; and Department of Pediatrics, Vanderbilt University, Nashville, Tenn (Dr Cooper).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Effectiveness of the 7-Valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease in the First Decade of Life
Adamkiewicz et al.
Pediatrics 2008;121:562-569.
ABSTRACT
| FULL TEXT
The Effect of the Pneumococcal Conjugate Vaccine on Children with Sickle Cell Disease
Villella
AAP Grand Rounds 2007;18:1-2.
FULL TEXT
Sickle Cell Disease: A Question of Equity and Quality
Smith et al.
Pediatrics 2006;117:1763-1770.
ABSTRACT
| FULL TEXT
Research for Newborn Screening: Developing a National Framework
Botkin
Pediatrics 2005;116:862-871.
ABSTRACT
| FULL TEXT
Follow-up Testing Among Children With Elevated Screening Blood Lead Levels
Kemper et al.
JAMA 2005;293:2232-2237.
ABSTRACT
| FULL TEXT
|
